Spero Therapeutics (SPRO) Receivables (2022 - 2026)

Spero Therapeutics (SPRO) has reported Receivables for 5 consecutive years, with -$19000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables fell 100.07% year-over-year to -$19000.0; the trailing twelve-month figure through Jun 2026 stood at -$19000.0 (down 100.07% YoY), and the FY2025 full-year result was $22.3 million, down 57.5% from the prior year.
• Receivables retreated to -$19000.0 in Q2 2026 per SPRO's latest filing, from $44000.0 in the prior quarter.
• Across five years, Receivables topped out at $55.5 million in Q2 2024 and bottomed at -$19000.0 in Q2 2026.
• Historically, Receivables has averaged $27.9 million across 5 years, with a median of $25.4 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Receivables soared 36318.32% in 2023, then sank 100.07% in 2026.
• Over 5 years, Receivables stood at $131000.0 in 2022, then jumped by 36318.32% to $47.7 million in 2023, then gained by 4.34% to $49.8 million in 2024, then sank by 52.2% to $23.8 million in 2025, then slumped by 100.08% to -$19000.0 in 2026.
• According to Business Quant data, Receivables over the past three periods registered -$19000.0, $44000.0, and $23.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.